Upgrades, downgrades, and outlook changes from major analysts.
Coverage of analyst actions including upgrades, downgrades, initiations, and price-target changes. This category tracks how institutional research influences market perception, momentum shifts, and short-term price behavior.
3,516 total articles
Needham has upheld its Hold rating on Intel following a fourth-quarter financial performance that surpassed earnings expectations but was tempered by below-par revenue guidance and persistent supply constraints. Intel's stock has shown remarkable gains over the past year, yet concerns linger over its forward outlook and production bottlenecks impac…
Leerink Partners has upgraded Relmada Therapeutics Inc from Market Perform to Outperform, assigning a price target significantly higher than the current stock price, based on the potential of Relmada's bladder cancer drug NDV-01. After discontinuing its previous depression therapy REL-1017, Relmada is focusing on oncology with NDV-01, a sustained-r…
JPMorgan has lifted its price target for Intel Corporation to $35 from $30, citing robust demand for server CPUs as a key driver, despite guidance that fell short of analyst expectations. Intel’s stock currently trades significantly above JPMorgan’s revised target, reflecting strong market gains. While supply challenges are anticipated to ease, con…
Keefe, Bruyette & Woods (KBW) has increased the price target for Equity Bancshares (NYSE: EQBK) from $47.00 to $49.00 while keeping its Market Perform rating. This decision follows Equity Bancshares' notable earnings performance with EPS surpassing projections despite marginally lower pre-provision net revenue. The institution demonstrated robust r…
Keefe, Bruyette & Woods (KBW) has raised its price target for Great Southern Bancorp (NASDAQ: GSBC) to $63 from $61, following the company’s robust fourth-quarter 2025 earnings report. The bank’s earnings per share and revenue exceeded expectations, supported by stable net interest margins, increased fee income, and controlled expenses. Despite som…
Keefe, Bruyette & Woods raised its price target on Horizon Bancorp to $21 from $19, endorsing an Outperform rating after the bank reported better-than-expected earnings. The bank’s higher pre-provision net revenue and net interest margin contributed to stronger top-line performance. Updated guidance and optimistic margin outlook prompted increased …
Keefe, Bruyette & Woods has increased its price objective for Banc of California to $23, citing robust growth metrics and return improvements that support the stock's valuation. The bank's latest earnings surpassed expectations, reinforcing confidence among analysts and prompting revisions to future earnings projections.
RBC Capital has increased the price target for Definium Therapeutics Inc to $36 from $20 and reaffirmed an Outperform rating. This adjustment is based on heightened expectations for the commercial success of Definium’s lead candidate, DT120, currently in late-stage trials for generalized anxiety disorder. The company’s market value stands near $1.6…
Keefe, Bruyette & Woods has increased its price target for Live Oak Bancshares to $146 from $132 and maintained an Outperform rating after the bank's fourth-quarter results exceeded analyst estimates. The bank showcased stronger-than-expected earnings and revenue growth while maintaining stable credit performance. However, KBW anticipates a reversa…
RBC Capital has increased its price target for Compass Pathways to $21, maintaining an Outperform rating amid advancing clinical developments and promising market insights from recent psychedelics symposiums. The company’s shares have shown notable gains over the past year, with excitement building ahead of upcoming trial data.
Following Abbott Laboratories' release of its fourth-quarter earnings results, Oppenheimer has lowered its price target on the healthcare giant to $132 from $140 but retained its Outperform rating. The company's Q4 revenue and earnings per share fell short of estimates, influenced in part by underperformance in the Nutrition segment. Despite a rece…
TD Cowen has lowered its price target for McCormick & Company to $75 from $82, following the company's fourth-quarter earnings miss and subdued fiscal 2026 guidance. Higher input costs and accelerated ERP spending contributed to these challenges, leading to tempered growth expectations. Despite these headwinds, the firm retains its Buy rating, citi…
Evercore ISI has reduced its price objective for CSX to $40 from $41 while keeping an Outperform rating on the company's stock. The adjustment follows CSX's fourth-quarter 2025 earnings report, which revealed earnings per share below estimates and volumes and yields underperforming across segments. Despite these challenges, the company forecasts mo…
BTIG has boosted its price target for FTAI Aviation to $335 from $230, maintaining a Buy rating after the company announced a multi-year partnership with CFM International for component and repair support on CFM56 engines. This agreement reinforces FTAI's business trajectory and alleviates concerns about OEM relations. Shares have surged notably ov…
TD Cowen has maintained its Buy rating on Check Point Software stock, setting a $285 price target that suggests considerable market upside. The firm highlights ongoing demand from firewall updates and rapid uptake of Harmony Email and SASE solutions as drivers for the company's positive near-term momentum. Additional analyst endorsements and recent…
Wells Fargo has adjusted its price target for Mosaic (NYSE:MOS) downward to $27 from $28, maintaining an Equal Weight rating. The revision reflects diminished fourth-quarter expectations tied to weaker conditions in the Brazilian market and SSP production cutbacks. Mosaic’s Q4 and full-year 2025 earnings estimates have also been trimmed. Concurrent…
Wells Fargo has increased its price target for Procter & Gamble (NYSE:PG) to $165, up from $158, while reiterating an Overweight rating following the company's fiscal second-quarter earnings. Despite the results meeting modest expectations, the firm points to solid international operations and the possibility of an improved U.S. market as factors t…
Wells Fargo has increased its price target for Clorox to $115 from $108 after the company announced its acquisition of GOJO Industries, producer of Purell hand sanitizer, for $2.25 billion in cash. The move is viewed as a strategic effort to enhance Clorox's product portfolio and growth prospects. The acquisition is expected to be neutral to earnin…
Shares of SLM Corp rose in after-market trading after Wells Fargo increased its price target to $32.00 from $30.00, maintaining an Overweight rating on the student lending firm. The move follows the release of fourth-quarter earnings that exceeded estimates and an outlook signaling robust growth in earnings per share through 2027. Despite some metr…
Wells Fargo has trimmed its price objective for Abbott Laboratories to $122 from $146 while reiterating an Overweight rating. The revision follows Abbott's fourth-quarter earnings release showing a revenue shortfall attributed primarily to the Nutrition segment alongside other temporary setbacks. Despite these challenges, the company’s earnings per…
Wells Fargo has adjusted its price target on RLI Corp to $59 from $62, maintaining an Equal Weight rating despite the company's slower-than-expected revenue growth. The insurer prioritizes profitability over expansion, holding a robust 24% return on equity and consistent dividends, even as property market challenges temper revenue forecasts for 202…
UBS has downgraded its rating on Northern Star Resources from Buy to Neutral, lowering the price target in response to recent quarterly production shortfalls and increased cost projections. Despite trading near a 52-week high, concerns about production output and escalating expenses have tempered bullish sentiment, with UBS adjusting its forecasts …
BofA Securities has increased its price target on Sanmina-SCI Corp. to $190 from $180, while retaining a Neutral rating as the company approaches its fiscal Q1 2026 earnings release. Market attention centers on Sanmina's evolving revenue dynamics, driven by a transition from NVIDIA to AMD rack builds, and the integration challenges linked with its …
Research from Aletheia indicates that AMD's server CPU business may outperform existing expectations, with recent feedback from cloud service providers and suppliers pointing to stronger market conditions for fiscal 2026. Key investment firms maintain bullish views on AMD, citing solid demand and near sell-out of server CPUs through 2026, while str…
Roth/MKM has initiated a Buy rating on Insmed (NASDAQ:INSM), setting a $212 price target that indicates significant potential appreciation from present levels. The firm's analysis points to the strong future prospects of Insmed's Brinsupri and Arikayce therapies, underpinned by favorable trial expectations and market adoption. Despite recent revenu…
